Skip to main content
Premium Trial:

Request an Annual Quote

NextGen to Offer Biomarker Services; Taps Pisano as CEO

NEW YORK (GenomeWeb News) - NextGen Sciences said today that it will now offer protein biomarker services, including assay development and validation, and that it has named Mike Pisano, the former head of Protein Research Services, to be CEO of the company.
 
NextGen said its biomarker services are supported by the proteomics know-how that it acquired when it bought PRS in 2006, and by its investments into technologies such as ThermoFisher’s OrbiTrap and its triple quad mass spectrometers.
 
The new services include monitoring and verification of protein biomarkers from pre-clinical and clinical samples, and identification of putative protein biomarkers and proteins of interest, NextGen said.
 
Pisano said the company already is “working with a number of major customers to develop robust, accurate and precise assays to meet the needs of their clinical biomarker projects.”

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.